Loading...
•
Dec 31, 2023
Globus Medical Q4 2023 Earnings Report
Globus Medical's Q4 2023 results were announced, showcasing significant revenue growth due to the NuVasive merger.
Key Takeaways
Globus Medical reported a significant increase in worldwide net sales for Q4 2023, driven by the merger with NuVasive and increased volume of spine product sales and enabling technology volume. GAAP net income and EPS decreased, while non-GAAP net income and EPS increased. The company reaffirms its full year 2024 revenue and non-GAAP EPS guidance.
Worldwide net sales increased by 124.6% to $616.5 million.
GAAP net income was $15.0 million.
GAAP diluted EPS was $0.11, and non-GAAP diluted EPS was $0.60.
Non-GAAP adjusted EBITDA was $170.0 million, representing 27.6% of net sales.
Globus Medical
Globus Medical
Globus Medical Revenue by Segment
Globus Medical Revenue by Geographic Location
Revenue by Segment
Musculoskeletal Solutions Revenue
CapyFin.comEnabling Technologies Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company reaffirms its full year 2024 revenue guidance range of $2.450 billion to $2.475 billion and fully diluted non-GAAP earnings per share range between $2.68 to $2.70.
Revenue & Expenses
Visualization of income flow from segment revenue to net income